12 patients won't be enough to approve MPL for global use but it should be enough to gain the orphan drug designation.
If companies have less than 2 quarters of funding they just need to answer a few extra questions in their quarterly report. I've held a few companies that have done this without consequence.
12 patients won't be enough to approve MPL for global use but it...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.005(2.94%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.0¢ | $83.08K | 474.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 376717 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 144077 | 1 |
View Market Depth
| Last trade - 15.41pm 10/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |